CurrentColorado Rocky Mountain Health PlansPolicy N/A

Prior authorization for Cytokine and CAM Antagonists: T‑Lymphocyte Inhibitors

A prior authorization request form and criteria template for use of cytokine and CAM antagonist drugs (T‑lymphocyte inhibitors) for diagnoses including GVHD, juvenile idiopathic arthritis, psoriatic arthritis, and rheumatoid arthritis; intended for prescribers requesting coverage from the payer.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyPrior authorization for Cytokine and CAM Antagonists: T‑Lymphocyte Inhibitors

Policy CodePolicy N/A

Change TypeAdministrative — no material clinical changes

Effective DateN/A

Next Review DateN/A

Key ActionComplete and fax the prior authorization form (all sections) with chart notes and prior medication trial documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4diagnoses with question sets

24form questions (approx.)

24prior trial entries required

24chart notes required

Coverage Criteria for Indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Polyarticular Juvenile Idiopathic Arthritis

Polyarticular Juvenile Idiopathic Arthritis — covered when ALL of the following are met

PJIJA Initial/Continuation: Patient has trialed at least one non‑Cytokine and CAM DMARD (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, azathioprine, cyclosporine) that was ineffective, unless all are contraindicated or not tolerated [minimum trial of 3 months]>= 3 months

checkboxed question 10

Continuation: For continuation, documentation demonstrating disease stability or a positive clinical response (improvement in joint pain, swelling, activities of daily living, reduction in disease flares) must be submitted

question 11

Psoriatic Arthritis

Psoriatic Arthritis — covered when ALL of the following are met

PsA Initial: Patient has had treatment with at least one non‑Cytokine and CAM disease‑modifying antirheumatic drug (DMARD) that was ineffective, contraindicated or not tolerated [minimum trial of 3 months]>= 3 months

question 12

Active/severe disease: Provider documents presence of active, severe disease via assessment

question 13

High‑risk features: Presence of erosive disease OR elevated CRP/ESR OR long‑term damage interfering with function OR major impairment of quality of life due to high disease activity

question 14

Continuation: For continuation, documentation demonstrating disease stability or a positive clinical response must be submitted

question 15

Rheumatoid Arthritis

Rheumatoid Arthritis — covered when ALL of the following are met

Baseline assessments: Baseline disease activity assessments submitted (e.g., DAS28 with CRP or ESR, SDAI, CDAI, RAPID3, PAS II)

question 16

Prior DMARD trial: Patient has had treatment with at least one non‑Cytokine and CAM DMARD (e.g., methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine, azathioprine) that was ineffective unless contraindicated or not tolerated [minimum trial of 3 months]>= 3 months

question 17

Continuation: For continuation, documentation demonstrating disease stability or improvement in disease activity scores must be submitted

question 18

Graft Versus Host Disease (GVHD)

Graft Versus Host Disease — covered when applicable conditions are met

Chronic GVHD: Requested drug will be used as additional therapy in combination with corticosteroids for chronic GVHD OR patient has no response (steroid‑refractory) to first‑line therapy options

question 7

aGVHD prophylaxis with HSCT: For HSCT from a matched or 1‑allele mismatched unrelated donor, requested drug will be used for prophylaxis of acute GVHD in combination with a calcineurin inhibitor and methotrexate and patient will receive EBV prophylaxis for 6 months post‑transplant

question 8

Prior exposure: If patient received the requested medication previously, dates and duration of prior treatment must be indicated

question 9

The form does not print any explicit exclusion list; however, it requires completion of Section D (Previous Medication Trials) and asks providers to explain in Section E why preferred products were not tried. This implies that exclusions are handled operationally by requiring documentation of prior preferred therapies and justification when those agents were not used. See Section D for the required prior‑therapy fields and Section E for the explanation of why preferred medications would not meet the patient's needs.

Because the form specifically asks whether the request is for a continuation and whether the patient has prior trials of preferred Cytokine and CAM agents from the Apple Health Preferred Drug List, requests lacking those documented trials or explanations may be subject to step therapy or denial processes based on the payer’s preferred‑first expectations rather than a named exclusion on the form.

The form requires documentation of prior medication trials in Section D and asks, for non‑preferred requests, that providers list prior preferred Cytokine and CAM medications and durations or explain why preferred products were not tried in Section E. If those required prior trials or adequate dates/durations are not documented, the form indicates the request may not meet medical necessity requirements and could be denied or delayed.

Providers should ensure Section D contains specific medication names, dates of therapy, durations, and reasons for discontinuation or failure, and that Section E explains why preferred options were inappropriate when applicable. Missing or incomplete prior‑trial documentation is highlighted by the form as a controllable risk to authorization.

Provider Submission Requirements and Actions

Prior Authorization

Form submission

Providers must complete the entire Prior Authorization Request Form (all sections A–E) and fax it to 866-940-7328. Allow at least 24 hours for review. Call 800-310-6826 with questions. Incomplete forms or missing pages may delay processing.

Fax: 866-940-7328
Helpline: 800-310-6826
Allow ≥ 24 hours for review

Step Therapy

Prior medication trial requirement

When requesting a non-preferred medication, document prior trials of preferred Cytokine and CAM agents from the PDL — list each medication and the duration of trial, or provide a clear explanation why preferred products were not tried (e.g., contraindication, intolerance).

List medication name and duration for each preferred agent tried or
Explain why preferred agents were not appropriate

Documentation Required

Missing clinical documentation

Failure to attach chart notes and supporting clinical documentation with the PA request may result in denial or delay. For continuation requests, include objective evidence of disease stability or positive clinical response (e.g., DAS28 with CRP/ESR, SDAI, CDAI, RAPID3, PAS II where applicable).

CHART NOTES ARE REQUIRED WITH THIS REQUEST
Include baseline and follow-up assessments as applicable (see disease-specific questions)

Denial Risk

Missing prior trial documentation

If Section D does not include prior trial dates and durations (or clear reasons trials were not done) the request may be delayed or denied. Provide start/end dates or duration of therapy and reason for discontinuation for each prior medication.

Section D must list Dates of Therapy and Reason for failure/discontinuation for each prior medication

Documentation Required

Required submission documents

Required submission documents: completed PA form including Sections A–E (Sections C–E must specify medication, strength, directions, quantity, diagnosis with ICD‑10 code, Section D prior medication trials with dates/duration/reasons, and Section E explanation of why preferred meds are unsuitable). Also include weight (kg) with date, specialty of prescriber/consulting clinician, and any disease‑specific assessments (e.g., RA baseline scores).

Completed Sections A–E of the PA form
Medication details: name, strength, directions, quantity
Diagnosis with ICD‑10 code and relevant disease assessments
Section D: prior medication trials with dates/duration and reasons for failure
Section E: explanation why preferred medications would not meet patient needs
Patient weight (kg) and date taken
Attach chart notes and supporting clinical documentation

Step Therapy

Preferred‑first/step therapy

Preferred‑first/step therapy: Requests for non‑preferred agents require documentation that one or more preferred Cytokine and CAM medications on the Preferred Drug List were tried and were ineffective, contraindicated, or not tolerated. If a preferred agent was not tried, provide clinical rationale in Section D/E.

State which preferred PDL agents were tried and duration of each trial
If no preferred trial, document contraindication/intolerance or clinical justification

OpenPayer

Prior authorization for Cytokine and CAM Antagonists: T‑Lymphocyte Inhibitors

Coverage Criteria for Indications

Coding and Trial Duration

Provider Submission Requirements and Actions

Background

Definitions and Supporting Items